& Burne, T
The liraglutide group also showed a lower incidence of prediabetes and diabetes than the control group [11,13]
It prompts the pancreas to secrete insulin, suppresses glucagon, slows gastric emptying so food stays in the stomach longer, and acts on receptors in the hypothalamus and brainstem to reduce appetite
Cagrilintide acts through amylin and calcitonin receptor systems, and recent evidence suggests that its body-weight-lowering effects are mediated, at least in part, through brain amylin receptor 1 and 3 signalling (111)
Gastroparesis from semaglutide prevent food from moving through the stomach as intended, which could lead to serious health problems, such as: Blockages in the small intestine Development of hard masses of food known as bezoars Difficulty managing blood sugar levels Extreme weight loss leading to malnutrition Intestinal blockages These are just a few potential risks that are frequently seen with semaglutide gastroparesis
Neither compound has published the kind of long-term hard-outcome data (cardiovascular events, mortality) that ultimately defines a metabolic drugs value, because both are too early in development for that